Contributo in atti di convegno, 2016, ENG
F. Mingoia 1), C. Di Sano 2), M. Fazzari 3), A. Martorana 4), A. Lauria 4), V. Bravatà 5) G. I. Forte 5), L. Minafra 5)
1)ISMN-CNR Palermo 2) IBIM-CNR Palermo 3) RIMED Palermo 4) STEBICEF, Università di Palermo 5) IBFM-CNR Cefalù
Thanks to a new synthetic approach recently developed by us1, a new series of pyrrolo[3,2-c]quinoline (PQ) derivatives, has been synthesized permitting us to introduce suitable functional groups in different positions of the scaffold. The latter known for possessing a wide range of biological activities, including anticancer2. The one dose screening (10 ?M) performed by the National Cancer Institute (NCI, USA) against 60 types of tumor cell lines including several panel such as leukemia, lung, renal, CNS, prostate, breast, melanoma, ovarian and colon cancers, allowed us to identify a clear profile of selectivity and potency. Thus, for the most promising derivatives, we undertaken in dept biological investigations. In detail, the 4-substituted piperonil one, which exhibited a preliminary 58% and 18% of growth inhibition in the NCI testing against MCF-7 and MDA-MB-231, respectively, are here submitted to further investigations in order to get new insights on the mode of action. Therefore, a dose response profile at 24, 48 and 72 h was undertaken. More details will be shown at the poster session
Tecnologie, Ricerca di base, interdisciplinare traslazionale in ambito biomedico. Simposio IBIM-CNR/STEBICEF, Palermo IV meeting IBIM-CNR/STEBICEF, pp. 70–70, Palermo, 15/12/2016, 16/12/2016
Antiproliferative, Pyrrolo[3, 2-c]quinoline derivatives, breast cancer
Minafra Luigi, Mingoia Francesco Michele, Di Sano Caterina
ID: 391957
Year: 2016
Type: Contributo in atti di convegno
Creation: 2018-09-27 17:36:18.000
Last update: 2020-09-30 14:42:30.000
External IDs
CNR OAI-PMH: oai:it.cnr:prodotti:391957